United States Next Generation Sequencing (NGS) Market to Hit $10.77 Billion by 2033, Driven by Genomic Analysis & Molecular Diagnostics

Leander, Texas and Tokyo, Japan - Dec.05.2025
As per DataM intelligence research report" Next Generation Sequencing (NGS) Market size reached US$ 13.42 Billion in 2024 and is expected to reach US$ 35.92 Billion by 2033, growing at a CAGR of 11.6% during the forecast period 2025-2033." Falling costs and growing applications in diagnostics and research are expanding the NGS market globally.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/next-generation-sequencing-ngs-market?Prasad

United States: Recent Industry Developments

✅ In November 2025, The FDA approved Kura Oncology's ziftomenib for AML patients with NPM1 mutations identified by NGS This approval validates the use of NGS companion diagnostics for guiding targeted leukemia therapy It cements NGS as a standard of care for acute myeloid leukemia in the U.S.

✅ In October 2025, Illumina launched the NovaSeq Xr, a renewed high-throughput sequencer with lower reagent costs The system is designed to make whole-genome sequencing affordable for routine clinical screening It aims to democratize access to genomic medicine across U.S. health systems

✅ In September 2025, Thermo Fisher Scientific received pre-market approval for its "Oncomine" Dx Target Test extension The update adds new gene targets relevant to recently approved therapies for lung cancer It ensures U.S. patients can be matched to the latest precision medicines

✅ In August 2025, Ultima Genomics announced a partnership with a major U.S. reference lab to deploy its "$100 genome" platform The collaboration aims to scale up population health studies and carrier screening It disrupts the U.S. sequencing market with a low-cost high-volume solution

Japan: Recent Industry Developments

✅ In December 2025, Sysmex Corporation launched a new NGS panel specifically designed for Japanese hereditary cancer screening The panel covers genes more prevalent in the East Asian population improving diagnostic yield It localizes genomic medicine tools for better accuracy in Japan

✅ In November 2025, The National Cancer Center Japan began a "Liquid Biopsy" NGS project for early cancer detection The project uses blood samples to detect circulating tumor DNA before symptoms appear It promotes non-invasive cancer screening methods in Japan

✅ In October 2025, Konica Minolta's subsidiary REALM IDx partnered with Japanese university hospitals to standardize NGS reporting The initiative aims to create a unified format for genomic test results to facilitate data sharing It improves the utility of genomic data for research and treatment in Japan

✅ In September 2025, Canon Medical Systems acquired a bioinformatics startup to strengthen its NGS analysis capabilities The acquisition allows Canon to offer an end-to-end solution from sequencing to clinical reporting It expands Canon's presence in the Japanese in-vitro diagnostics market

Next Generation Sequencing (NGS) Market: Drivers
The next-generation sequencing (NGS) market is expanding rapidly as genomic research and precision medicine gain traction. NGS enables high-throughput DNA and RNA sequencing for disease diagnosis, biomarker discovery, and personalized therapeutics. Advances in sequencing platforms, bioinformatics tools, and sample preparation technologies are improving speed, accuracy, and cost-effectiveness. Increasing investment in genomics research, cancer studies, and rare disease analysis is driving market adoption. Rising awareness of preventive healthcare and early disease detection further supports growth.

Collaboration among biotech firms, research institutions, and hospitals is accelerating NGS application in clinical diagnostics, pharmacogenomics, and microbiome studies. Integration with AI and cloud computing platforms enhances data analysis and interpretation. Growth in population genomics, prenatal testing, and immunogenomics expands commercial opportunities. Regulatory approvals and reimbursement support wider clinical adoption. With ongoing technological innovation and rising demand for personalized medicine, the NGS market is poised for sustained expansion.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/next-generation-sequencing-ngs-market?Prasad

Next Generation Sequencing (NGS) Market: Major Players
Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Qiagen, Eurofins Scientific, Revvity (PerkinElmer Inc.), Takara Bio Inc., Illumina Inc., Alithea Genomics SA, and NewBiologix SA, among others.

Segment Covered in the Next Generation Sequencing (NGS) Market:
By Product Type
Instruments dominate with 42% share, driven by high-throughput sequencers, benchtop sequencers, and automation-compatible platforms. Consumables account for 35%, including reagents, kits, and library prep materials, essential for NGS workflows. Software and services contribute 23%, supporting data analysis, storage, and bioinformatics pipelines. The combination ensures efficient, accurate, and scalable sequencing capabilities. Rising demand from clinical research, genomics studies, and precision medicine fuels adoption across laboratories and hospitals globally.

By Application
Clinical diagnostics lead with 38% share, including oncology, genetic disease screening, and infectious disease profiling. Research applications hold 32%, covering functional genomics, biomarker discovery, and transcriptomics. Drug discovery and development contribute 18%, supporting pharmacogenomics, target identification, and personalized therapeutics. Agriculture and veterinary genomics represent 8%, while other applications hold 4%, including environmental and microbial sequencing. NGS enables rapid, high-accuracy insights across diverse biological fields.

By Technology
Sequencing by synthesis dominates with 45% share, powering most high-throughput platforms for clinical and research applications. Sequencing by ligation accounts for 20%, offering accuracy in specific genomic regions. Ion semiconductor sequencing holds 15%, favored for targeted and rapid sequencing. Nanopore and single-molecule real-time (SMRT) technologies contribute 12%, supporting long-read applications and complex genome assemblies. Other emerging technologies represent 8%, enhancing scalability and data resolution for niche applications.

By End User
Academic and research institutes lead with 36% share, leveraging NGS for genomics studies, functional analysis, and biomarker discovery. Hospitals and clinics hold 28%, implementing NGS for diagnostic and personalized medicine purposes. Pharmaceutical and biotechnology companies contribute 24%, employing NGS in drug development, target validation, and clinical trials. Contract research organizations (CROs) account for 8%, providing outsourced sequencing and bioinformatics services. Other end users hold 4%, including agriculture and environmental genomics labs.

Regional Analysis
North America leads with 34% share, driven by strong R&D infrastructure, early adoption of NGS platforms, and extensive genomics initiatives in the U.S. and Canada. Europe holds 26%, supported by Germany, France, and the UK, with advanced genomics research, clinical sequencing adoption, and regulatory support for precision medicine. Asia Pacific captures 28%, led by China, Japan, India, and South Korea, with increasing investments in genomics research, diagnostics, and healthcare digitization. Latin America contributes 6%, with adoption mainly in Brazil and Mexico for clinical and research purposes. Middle East & Africa hold 6%, driven by emerging genomic programs and collaborations in GCC countries and South Africa.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=next-generation-sequencing-ngs-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?Prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.